Hola,
Are you new here?

CENSUS

financed

Cell Based Models for Neurodegeneration Study and Use in Screening

1. Treatment of neurodegenerative disease is an unmet clinical challenge and patient care is a growing, unsustainable global healthcare burden. The project will produce novel tools to address this challenge. 2. The consortium will... see more

30/09/2019

ACS

3M€

Project Budget: 3M€

Project leader

AvantiCell Science Ltd No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 5 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2019-09-30

FTIPilot-01-2016: Fast Track to Innovation Pilot Specific Challenge:Innovation is fostered when new ideas can emerge and easily translate into socio-...

I+D

Cerrada does 9 years

0% 70% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

ACS

675.74K€ | Leader

FERRER INTERNACIONAL

1.48M€ | participant

253.75K€ | participant

PHENOCELL

410.85K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 36 months Date Start: 2016-09-13
End date: 2019-09-30

Project leader

AvantiCell Science Ltd No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 3M€

participation deadline Sin fecha límite de participación.

Project description 1. Treatment of neurodegenerative disease is an unmet clinical challenge and patient care is a growing, unsustainable global healthcare burden. The project will produce novel tools to address this challenge. 2. The consortium will deliver a set of innovative analytical tools for neurodegenerative drug discovery using a combination of stem cell biology and novel biomaterials assembled by additive manufacturing. 3. The toolset will be analytical kits containing induced pluripotent stem cell (iPSC)-derived human neural cells in 3D culture formats, delivered to end-users in multiwell plates ready for industrial screening. 4. Project outputs will be realised by an inter-disciplinary consortium of four SME commercial partners in three European countries, each partner supplying a specific, essential skillset. 5. iPSC-derived neural cells will be produced by Phenocell sarl (F) using stem cell differentiation protocols already shown to generate glial or neuronal cell lineages, and to reinstate donor disease phenotypes. 6. Bio-printer instrumentation and printable bio-inks to manufacture 3D scaffolds enabling 3D cell culture will be contributed by Cellink (SE). 7. 3D culture models will be customised for neural/neurodegenerative cell culture by inclusion of peptide dendrons with biological functionality using mature chemistry proprietary to Tissue Click Ltd (UK). 8. Cell-based analysis products will be validated, and made user-friendly by in situ cell cryopreservation and analytical processes familiar to AvantiCell Science Ltd (UK). 9. Each contributing technology is at TRL 6, and each has commercial utility in simpler combinations. The project assembles them in first-to-market formats beyond the current state of the art. 10. The CENSUS project output, comprising iPSC-derived neural cells cryopreserved in single-cell and co-culture 3D formats will deliver exceptional analytical precision and predictive value, unprecedented end-user convenience and strong commercial advantage

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers